ALLcrimesfood&drugstaxestelecomcommercehealthconservationtransportationagricultureveteransbrowse all titles »
0

21 U.S.C. § 379aaSerious adverse event reporting for nonprescription drugs

submitted 88 years ago by Pub. L. 109-462 to r/title-21-FOOD-AND-DRUGS · 1,149 words · no verdicts yet

in plain englishAI-generated · not legal advice

This law makes companies report serious health problems linked to nonprescription drugs. The company named on the drug's label must send the report to the Secretary within 15 business days. Reports use the MedWatch form, must be kept six years, and states can't add different mandatory rules.

This section requires companies to report serious health problems tied to over-the-counter drugs, and sets rules for how those reports work. (a) Definitions. (1) "Adverse event" means any health-related event connected to using a nonprescription drug that is bad for the person, including: (A) an event from an overdose, whether accidental or intentional; (B) an event from abusing the drug; (C) an event from withdrawing from the drug; and (D) any time the drug simply fails to work the way it is expected to. (2) "Nonprescription drug" means a drug that is (A) not subject to section 353(b) of this title (the prescription-drug rule), and (B) not subject to approval under an application filed under section 355 of this title. (3) "Serious adverse event" is an adverse event that (A) results in (i) death, (ii) a life-threatening experience, (iii) hospitalization as an inpatient, (iv) a lasting or significant disability or incapacity, or (v) a birth defect; or (B) requires medical or surgical treatment, based on reasonable medical judgment, to prevent one of those outcomes. (4) "Serious adverse event report" means a report required under subsection (b). (b) Reporting requirement. (1) The manufacturer, packer, or distributor whose name appears on the label of a nonprescription drug sold in the United States — called the "responsible person" — must send the Secretary any report it receives of a serious adverse event tied to that drug's use in the United States, along with a copy of the label from the retail package. (2) A retailer named on the label as the distributor can agree to let the manufacturer or packer file these reports instead, as long as the retailer forwards to them every adverse event report it receives through the address or phone number described in section 352(x) of this title. (c) Submission of reports. (1) The responsible person must send a serious adverse event report to the Secretary no later than 15 business days after receiving it. (2) If the responsible person gets new medical information tied to an already-submitted report within one year of the first report, it must send that new information within 15 business days of receiving it. (3) The Secretary must build systems so that duplicate reports, and related new information, get combined into a single report. (4) After giving notice and letting interested parties comment, the Secretary may excuse a company from the (1) and (2) deadlines if doing so would not hurt public health. (d) Contents of reports. Each report must be submitted on the MedWatch form, which the Secretary may adjust for nonprescription drugs, and may come with extra information. (e) Maintenance and inspection of records. (1) The responsible person must keep records of every adverse event report it receives for 6 years. (2)(A) It must let an "authorized person" see those records during an inspection done under section 374 of this title. (B) An "authorized person" is a Department of Health and Human Services officer or employee who has the credentials the Secretary requires and has been specifically designated by the Secretary to see these records. (f) Protected information. A serious adverse event report — including new medical information sent under (c)(2) — or any adverse event report sent in voluntarily, counts as: (1) a "safety report" under section 379v of this title, and may include a statement, kept with any publicly released version, denying that the report is an admission the product caused or contributed to the event; and (2) a record about an individual under section 552a of title 5 (the Privacy Act) and a medical-type file whose disclosure would break section 552 of title 5 (the Freedom of Information Act) — it cannot be released publicly unless all information that could identify a person is blacked out. (g) Rule of construction. Filing an adverse event report under this section is not, by itself, an admission that the drug caused or contributed to the event. (h) Preemption. (1) No state or local government may keep in place any law, regulation, order, or other requirement for mandatory adverse-event reporting on nonprescription drugs that is different from, adds to, or is not identical to this section. (2)(A) This does not stop the Secretary from giving adverse event reports and information to state, territory, or local health, food, or drug officials under a written agreement between the Secretary and that government. (B) Despite any other law, information in those reports that could identify a person may not (i) be made public under any state or other disclosure law, or (ii) otherwise be shared with anyone else without written consent from both the Secretary and whoever submitted the information. (C) A state, territory, or local government cannot use a safety report it gets from the Secretary in a way that conflicts with (g) or section 379v of this title. (i) Authorization of appropriations. Congress authorizes whatever money is needed to carry out this section.
the actual law source: uscode.house.gov ↗public domain
(a) Definitions

In this section:

(1) Adverse event

The term “adverse event” means any health-related event associated with the use of a nonprescription drug that is adverse, including—

(A)

an event occurring from an overdose of the drug, whether accidental or intentional;

(B)

an event occurring from abuse of the drug;

(C)

an event occurring from withdrawal from the drug; and

(D)

any failure of expected pharmacological action of the drug.

(2) Nonprescription drug

The term “nonprescription drug” means a drug that is—

(A)

not subject to section 353(b) of this title; and

(B)

not subject to approval in an application submitted under section 355 of this title.

(3) Serious adverse event

The term “serious adverse event” is an adverse event that—

(A)

results in—

(i)

death;

(ii)

a life-threatening experience;

(iii)

inpatient hospitalization;

(iv)

a persistent or significant disability or incapacity; or

(v)

a congenital anomaly or birth defect; or

(B)

requires, based on reasonable medical judgment, a medical or surgical intervention to prevent an outcome described under subparagraph (A).

(4) Serious adverse event report

The term “serious adverse event report” means a report that is required to be submitted to the Secretary under subsection (b).

(b) Reporting requirement
(1) In general

The manufacturer, packer, or distributor whose name (pursuant to section 352(b)(1) of this title) appears on the label of a nonprescription drug marketed in the United States (referred to in this section as the “responsible person”) shall submit to the Secretary any report received of a serious adverse event associated with such drug when used in the United States, accompanied by a copy of the label on or within the retail package of such drug.

(2) Retailer

A retailer whose name appears on the label described in paragraph (1) as a distributor may, by agreement, authorize the manufacturer or packer of the nonprescription drug to submit the required reports for such drugs to the Secretary so long as the retailer directs to the manufacturer or packer all adverse events associated with such drug that are reported to the retailer through the address or telephone number described in section 352(x) of this title.

(c) Submission of reports
(1) Timing of reports

The responsible person shall submit to the Secretary a serious adverse event report no later than 15 business days after the report is received through the address or phone number described in section 352(x) of this title.

(2) New medical information

The responsible person shall submit to the Secretary any new medical information, related to a submitted serious adverse event report that is received by the responsible person within 1 year of the initial report, no later than 15 business days after the new information is received by the responsible person.

(3) Consolidation of reports

The Secretary shall develop systems to ensure that duplicate reports of, and new medical information related to, a serious adverse event shall be consolidated into a single report.

(4) Exemption

The Secretary, after providing notice and an opportunity for comment from interested parties, may establish an exemption to the requirements under paragraphs (1) and (2) if the Secretary determines that such exemption would have no adverse effect on public health.

(d) Contents of reports

Each serious adverse event report under this section shall be submitted to the Secretary using the MedWatch form, which may be modified by the Secretary for nonprescription drugs, and may be accompanied by additional information.

(e) Maintenance and inspection of records
(1) Maintenance

The responsible person shall maintain records related to each report of an adverse event received by the responsible person for a period of 6 years.

(2) Records inspection
(A) In general

The responsible person shall permit an authorized person to have access to records required to be maintained under this section, during an inspection pursuant to section 374 of this title.

(B) Authorized person

For purposes of this paragraph, the term “authorized person” means an officer or employee of the Department of Health and Human Services who has—

(i)

appropriate credentials, as determined by the Secretary; and

(ii)

been duly designated by the Secretary to have access to the records required under this section.

(f) Protected information

A serious adverse event report submitted to the Secretary under this section, including any new medical information submitted under subsection (c)(2), or an adverse event report voluntarily submitted to the Secretary shall be considered to be—

(1)

a safety report under section 379v of this title and may be accompanied by a statement, which shall be a part of any report that is released for public disclosure, that denies that the report or the records constitute an admission that the product involved caused or contributed to the adverse event; and

(2)

a record about an individual under section 552a of title 5 (commonly referred to as the “Privacy Act of 1974”) and a medical or similar file the disclosure of which would constitute a violation of section 552 of such title 5 (commonly referred to as the “Freedom of Information Act”), and shall not be publicly disclosed unless all personally identifiable information is redacted.

(g) Rule of construction

The submission of any adverse event report in compliance with this section shall not be construed as an admission that the nonprescription drug involved caused or contributed to the adverse event.

(h) Preemption
(1) In general

No State or local government shall establish or continue in effect any law, regulation, order, or other requirement, related to a mandatory system for adverse event reports for nonprescription drugs, that is different from, in addition to, or otherwise not identical to, this section.

(2) Effect of section
(A) In general

Nothing in this section shall affect the authority of the Secretary to provide adverse event reports and information to any health, food, or drug officer or employee of any State, territory, or political subdivision of a State or territory, under a memorandum of understanding between the Secretary and such State, territory, or political subdivision.

(B) Personally-identifiable information

Notwithstanding any other provision of law, personally-identifiable information in adverse event reports provided by the Secretary to any health, food, or drug officer or employee of any State, territory, or political subdivision of a State or territory, shall not—

(i)

be made publicly available pursuant to any State or other law requiring disclosure of information or records; or

(ii)

otherwise be disclosed or distributed to any party without the written consent of the Secretary and the person submitting such information to the Secretary.

(C) Use of safety reports

Nothing in this section shall permit a State, territory, or political subdivision of a State or territory, to use any safety report received from the Secretary in a manner inconsistent with subsection (g) or section 379v of this title.

(i) Authorization of appropriations

There are authorized to be appropriated to carry out this section such sums as may be necessary.

Source credit: (June 25, 1938, ch. 675, § 760, as added Pub. L. 109–462, § 2(a), Dec. 22, 2006, 120 Stat. 3469.)

history & why it existsrecord from the source credit
  • 1938Enacted · Pub. L. 109-462 · 120 Stat. 3469

A history note hasn’t been published yet. The record shows enactment by Pub. L. 109-462 on 1938-06-25.

all 0 arguments · sorted by: best

0/280

no arguments yet — make the first case